NO2024011I1 - Quizartinib - Google Patents

Quizartinib

Info

Publication number
NO2024011I1
NO2024011I1 NO2024011C NO2024011C NO2024011I1 NO 2024011 I1 NO2024011 I1 NO 2024011I1 NO 2024011 C NO2024011 C NO 2024011C NO 2024011 C NO2024011 C NO 2024011C NO 2024011 I1 NO2024011 I1 NO 2024011I1
Authority
NO
Norway
Prior art keywords
quizartinib
Prior art date
Application number
NO2024011C
Other languages
English (en)
Original Assignee
Ambit Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp
Publication of NO2024011I1 publication Critical patent/NO2024011I1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
NO2024011C 2009-05-14 2024-03-14 Quizartinib NO2024011I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17847209P 2009-05-14 2009-05-14
US24397709P 2009-09-18 2009-09-18

Publications (1)

Publication Number Publication Date
NO2024011I1 true NO2024011I1 (no) 2024-03-14

Family

ID=42289326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2024011C NO2024011I1 (no) 2009-05-14 2024-03-14 Quizartinib

Country Status (18)

Country Link
US (2) US8865710B2 (no)
EP (1) EP2429524B1 (no)
AU (2) AU2010248860B2 (no)
CA (1) CA2761940C (no)
CY (1) CY1122765T1 (no)
DK (1) DK2429524T3 (no)
ES (1) ES2773315T3 (no)
FI (1) FIC20240009I1 (no)
HR (1) HRP20200255T1 (no)
HU (2) HUE048309T2 (no)
LT (1) LT2429524T (no)
NL (1) NL301265I2 (no)
NO (1) NO2024011I1 (no)
NZ (1) NZ596739A (no)
PL (1) PL2429524T3 (no)
PT (1) PT2429524T (no)
SI (1) SI2429524T1 (no)
WO (1) WO2010132787A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
KR101755725B1 (ko) 2009-03-23 2017-07-07 암비트 바이오사이언시즈 코포레이션 병용 요법을 이용한 치료 방법
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤
CN104513252B (zh) * 2013-09-26 2017-11-10 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MA40608A (fr) 2014-09-09 2016-03-17 Janssen Biotech Inc Polythérapies avec des anticorps anti-cd38
IL307913A (en) * 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
AU2016350717B2 (en) 2015-11-03 2023-08-10 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
PL2201018T3 (pl) 2007-09-19 2016-11-30 STAŁE POSTACIE ZAWIERAJĄCE N-(5-TERT-BUTYLOIZOKSAZOL-3-ILO)-N'-{4--[7-(2-MORFOLIN-4-YLOETOKSY)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-ILO]FENYLO}MOCZNIK, ICH KOMPOZYCJE ORAZ ICH ZASTOSOWANIA
PL2205244T3 (pl) * 2007-11-08 2014-01-31 Ambit Biosciences Corp Sposoby podawania N-(5-tert-butylo-izoksazol-3-ilo)-N’-{4-[7-(2-morfolin-4-ylo-etoksy)-imidazo-[2,1-b]-[1,3]-benzotiazol-2-ilo]-fenylo} mocznika do leczenia chorób proliferacyjnych
JP5686736B2 (ja) * 2008-11-06 2015-03-18 アムビト ビオスシエンセス コルポラチオン プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物
KR101755725B1 (ko) 2009-03-23 2017-07-07 암비트 바이오사이언시즈 코포레이션 병용 요법을 이용한 치료 방법
ES2605621T3 (es) 2009-11-05 2017-03-15 Ambit Biosciences Corporation Procedimiento para la preparación de derivados de imidazo[2,1-b][1,3] benzotiazol
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションAmbit Biosciences Corporation シクロデキストリンとの混合体を含有する錠剤

Also Published As

Publication number Publication date
PT2429524T (pt) 2020-03-02
EP2429524B1 (en) 2020-01-15
ES2773315T3 (es) 2020-07-10
AU2015230806A1 (en) 2015-10-15
HUE048309T2 (hu) 2020-07-28
CY1122765T1 (el) 2021-03-12
WO2010132787A1 (en) 2010-11-18
HUS2400008I1 (hu) 2024-04-28
NL301265I1 (nl) 2024-03-20
AU2010248860B2 (en) 2015-06-25
SI2429524T1 (sl) 2020-07-31
US20160051557A1 (en) 2016-02-25
US20120258081A1 (en) 2012-10-11
NZ596739A (en) 2014-01-31
US9555040B2 (en) 2017-01-31
FIC20240009I1 (fi) 2024-03-27
LT2429524T (lt) 2020-05-11
NL301265I2 (nl) 2024-06-05
AU2010248860A1 (en) 2011-12-22
CA2761940C (en) 2018-04-10
CA2761940A1 (en) 2010-11-18
EP2429524A1 (en) 2012-03-21
HRP20200255T1 (hr) 2020-09-04
PL2429524T3 (pl) 2020-08-24
DK2429524T3 (da) 2020-02-24
US8865710B2 (en) 2014-10-21

Similar Documents

Publication Publication Date Title
FIC20240009I1 (fi) Kitsartinibi
DK2414015T3 (da) Laryngoskopsystem
DE112010004215A5 (de) Hydrostataktor
DK2411442T4 (da) Umættet polyesterresin
BRPI1008827A2 (pt) deisobutenizador
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1014968A2 (pt) subalargador
DE112010004249A5 (de) Spindelaktor
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
DK2483126T3 (da) Skinnekøretøj
DK2506968T3 (da) Faujasit-zeolit
DE112010004865T8 (de) Lamellennassreibkupplung
BRPI1010159A2 (pt) bistuti
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
FI20090100A0 (fi) Biotinidaasimääritys
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
DE112010002351A5 (de) Klemmorrichtung
DE112010003843T8 (de) Lastansteuervorrichtung
DE202009005065U8 (de) Kartonverschließmaschine
DE102009034429A8 (de) Flachantenne
DE112010004370A5 (de) Solarkollektorsystern
ES1071436Y (es) Marquesina autoportante